A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
THOR MEDICAL ASA operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 0 | 0 | 0 | 0 |
| Net Income | -4.0M | -4.0M | -2.8M | -33M | -51M | -45M |
| EPS | $-0.02 | $-0.02 | $-0.01 | $-0.28 | $-0.54 | - |
| Free Cash Flow | -2.3M | -2.3M | -6.1M | -43M | -47M | -43M |
| ROIC | -16.2% | -12.3% | -4.5% | - | -117.8% | -109.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.16 | 0.20 | 0.02 | 0.03 | 0.04 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -4.1M | -4.1M | -680K | 0 | -52M | -46M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -12.5% | -13.8% | -17.0% | -282.8% | -290.0% | -233.4% |
| Shares Outstanding | 234M | 234M | 194M | 115M | 95M | - |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0 | 0 | 0 | 0 | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -46M | -52M | 0 | -680K | -4.1M | -4.1M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -45M | -51M | -33M | -2.8M | -4.0M | -4.0M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -109.0% | -117.8% | N/A | -4.5% | -12.3% | -16.2% |
| ROE | -233.4% | -290.0% | -282.8% | -17.0% | -13.8% | -12.5% |
| ROA | -132.6% | -150.8% | -141.6% | -12.9% | -11.3% | -10.2% |
| Cash Flow | ||||||
| Op. Cash Flow | -43M | -47M | -43M | -6.1M | -2.2M | -2.2M |
| Free Cash Flow | -43M | -47M | -43M | -6.1M | -2.3M | -2.3M |
| Owner Earnings | -44M | -48M | -44M | -6.3M | -2.7M | -2.7M |
| CapEx | 20K | 30K | 589K | 0 | 13K | 13K |
| Maint. CapEx | 1.6M | 1.3M | 1.2M | 31K | 223K | 223K |
| Growth CapEx | 0 | 0 | 0 | N/A | 0 | 0 |
| D&A | 1.6M | 1.3M | 1.2M | 31K | 223K | 223K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | 199K | 263K | 263K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -31M | -32M | -10M | 1.2M | -6.5M | -12M |
| Cash & Equiv. | 31M | 32M | 10M | 4.0M | 12M | 12M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.04 | 0.03 | 0.02 | 0.20 | 0.16 | 0.00 |
| Interest Coverage | -504.8 | -695.7 | N/A | -42.4 | N/A | N/A |
| Equity | 19M | 16M | 6.7M | 26M | 32M | 32M |
| Total Assets | 34M | 35M | 11M | 31M | 39M | 39M |
| Total Liabilities | 15M | 18M | 4.8M | 5.6M | 7.2M | 7.2M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | N/A | N/A | -2.0M | -5.9M | -5.9M |
| Working Capital | 19M | 16M | 6.8M | 3.9M | 10M | 10M |
| Current Assets | 33M | 34M | 11M | 4.3M | 12M | 12M |
| Current Liabilities | 14M | 18M | 4.6M | 422K | 2.1M | 2.1M |
| Per Share Data | ||||||
| EPS | N/A | -0.54 | -0.28 | -0.01 | -0.02 | -0.02 |
| Owner EPS | N/A | -0.51 | -0.38 | -0.03 | -0.01 | -0.01 |
| Book Value | N/A | 0.17 | 0.06 | 0.13 | 0.13 | 0.13 |
| Cash Flow/Share | N/A | -0.49 | -0.37 | -0.03 | -0.01 | -0.02 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | N/A | 94.9M | 115.3M | 193.8M | 234.5M | 234.5M |
| Valuation | ||||||
| P/E Ratio | N/A | -4.8 | -0.5 | -10.4 | -13.7 | -312.1 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 15.2 | 2.2 | 1.1 | 1.7 | 39.1 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -18.9% | -293.4% | -21.3% | -4.2% | -0.2% |
| Market Cap | 0 | 248M | 15M | 29M | 54M | 1.2B |
| Avg. Price | 2.07 | 2.65 | 0.78 | 0.12 | 0.13 | 5.26 |
| Year-End Price | 1.81 | 2.62 | 0.13 | 0.15 | 0.23 | 5.26 |
THOR MEDICAL ASA passes 0 of 9 quality checks, indicating weak fundamentals.
THOR MEDICAL ASA (TRMED-OL) has a 5-year average return on invested capital (ROIC) of -60.9%. This is below average and may indicate limited pricing power.
THOR MEDICAL ASA (TRMED-OL) has a market capitalization of $1.2B. It is classified as a small-cap stock.
THOR MEDICAL ASA (TRMED-OL) does not currently pay a regular dividend.
THOR MEDICAL ASA (TRMED-OL) operates in the Biotechnology industry, within the Healthcare sector.
THOR MEDICAL ASA (TRMED-OL) generated $-2 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
THOR MEDICAL ASA (TRMED-OL) has a debt-to-equity ratio of 0.16. This indicates a conservatively financed balance sheet.
THOR MEDICAL ASA (TRMED-OL) reported earnings per share (EPS) of $-0.02 in its most recent fiscal year.
THOR MEDICAL ASA (TRMED-OL) has a return on equity (ROE) of -13.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 5 years of financial data for THOR MEDICAL ASA (TRMED-OL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
THOR MEDICAL ASA (TRMED-OL) has a book value per share of $0.13, based on its most recent annual SEC filing.